Cargando…
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Autores principales: | Chugh, R., Griffith, K.A., Davis, E.J., Thomas, D.G., Zavala, J.D., Metko, G., Brockstein, B., Undevia, S.D., Stadler, W.M., Schuetze, S.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360153/ https://www.ncbi.nlm.nih.gov/pubmed/30726873 http://dx.doi.org/10.1093/annonc/mdy557 |
Ejemplares similares
-
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017) -
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis
por: Dillon, D.G.
Publicado: (2016) -
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015) -
Cixutumumab reveals a critical role for IGF-1 in adipose and hepatic tissue remodelling during the development of diet-induced obesity
por: Imrie, Helen, et al.
Publicado: (2022) -
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
por: Naing, A, et al.
Publicado: (2013)